Evidence-based treatments for gastrointestinal health
We are building a pipeline of evidence-based gastrointestinal health products, through in-house development and in-licencing / partnership opportunities.
Research
Stage 2 IBS Clinical Trial Phase II
Irritable Bowel Syndrome (IBS) trial
We are thrilled to announce that Anatara Lifesciences is now accepting applications for Stage 2 of our clinical trial on Irritable Bowel Syndrome (IBS).
By joining Stage 2 of our clinical trial, you can play a pivotal role in advancing IBS treatment options and potentially improve the quality of life for millions of individuals worldwide.
Research
Positive Outcome for Stage 1 GaRP Trial
Irritable Bowel Syndrome trial
has reached interim
We’re delighted to share that Stage 1 of the GaRP Irritable Bowel Syndrome (IBS) trial has reached its conclusion.
Our commitment to improving lives through research is stronger than ever.
As seen on
about
Meet Anatara
Innovative Solutions for Gastrointestinal Health:
Anatara Lifesciences (ASX: ANR)
Anatara Lifesciences (ASX: ANR) specialises in creating evidence-based, innovative products to address unmet needs in gastrointestinal health for both humans and animals. Our focus is on building a pipeline of gastrointestinal health products through our own research and development as well as strategic partnerships. Our core commitment is to deliver tangible benefits to patients and create significant value for our shareholders.
about IBS
Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care.
11
%
Products
& Pipelines
Developing products
for gastrointestinal health
Anatara Lifesciences is developing and commercialising innovative, evidence-based health products to address significant unmet need, with a particular focus on conditions that involve the complexity of the gastrointestinal tract
